A Study of TMC435 Plus Pegylated Interferon Alfa-2a & Ribavirin in

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, tolerability, and safety of 12-weeks of treatment with TMC435 plus pegylated interferon alfa-2a (PegIFNα-2a) and ribavirin (RBV) in previously untreated adult participants with genotype 1 or genotype 4 chronic Hepatitis C Virus (HCV) infection.

Clinical Trial Description

This is a multicenter, international study where all participants will receive triple therapy with the following 3 medications: TMC435 also referred to as simeprevir (formerly known as TMC435350) which is an investigational medication in development for the treatment of chronic hepatitis C virus (HCV) infection, pegylated interferon alfa-2a (PegIFNα-2a), and ribavirin (RBV). PegIFNα-2a and RBV are commercially available therapies for HCV infection. Participants will receive treatment with TMC435, PegIFNα-2a, and RBV for 12 weeks. If blood levels of HCV ribonucleic acid (RNA) monitored at Weeks 2, 4, and 8 are below 25 IU/mL, all treatment will be stopped at Week 12. If HCV RNA values are above 25 IU/mL at Weeks 2, 4, or 8, treatment with PegIFNα-2a and RBV will continue for an additional 12 weeks (up to Week 24) unless protocol-specified stopping criteria are met at Week 4 or 12, at which time all treatment will be discontinued. The study will be conducted in 3 phases: a screening phase of maximum 6 weeks, a treatment phase extending from Day 1 (baseline) up to 12 or 24 weeks depending on the response to treatment, and a posttreatment follow-up period of 24 weeks after the participant's last planned dose of study drug. The duration of the participation (excluding screening phase) for each participant will vary between 36 and 48 weeks, depending on the response to treatment. Blood samples for laboratory analysis will be obtained from participants at protocol-specified time points during the study and participant safety will be monitored throughout the study. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01846832
Study type	Interventional
Source	Janssen-Cilag International NV
Contact
Status	Completed
Phase	Phase 3
Start date	September 2013
Completion date	August 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04529421` - Assocation Between In-person Instruction and COVID-19 Risk
Recruiting	`NCT04081792` - Optimal Antibiotics for Operated Diabetic Foot Infections	N/A
Completed	`NCT04332861` - Evaluation of Infection in Obstructing Urolithiasis
Recruiting	`NCT04674657` - Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
Enrolling by invitation	`NCT05052203` - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Recruiting	`NCT00342589` - New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
Completed	`NCT03295825` - Heparin Binding Protein in Early Sepsis Diagnosis	N/A
Completed	`NCT03296423` - Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly	Phase 4
Withdrawn	`NCT04217252` - Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection	N/A
Recruiting	`NCT02899143` - Short-course Antimicrobial Therapy in Sepsis	Phase 2
Recruiting	`NCT02905552` - Myelodysplasic Syndromes and Risk Factors for Infection	N/A
Withdrawn	`NCT02904434` - Gastrointestinal Implications of Voriconazole Exposure
Active, not recruiting	`NCT02768454` - Antimicrobials Stewardship by Pharmacist	N/A
Completed	`NCT02219776` - Decreasing Infection In Arthroscopic Shoulder Surgery	N/A
Completed	`NCT02210169` - RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates	N/A
Recruiting	`NCT02098226` - Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts	N/A
Terminated	`NCT01441206` - Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants	Phase 1
Completed	`NCT01434797` - Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
Completed	`NCT01159834` - Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)	N/A
Recruiting	`NCT01085669` - Infection Rate of Vertical Expandable Prosthetic Titanium Rib Implants (VEPTR)	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms